SCHEMBL14073632

SCHEMBL14073632

Cn1cc(CC(=O)Nc2ccc3c(c2)NC(=O)CO3)c2ccccc21

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.56
▸ ALDH1A1 P00352 6/20 0.56
▸ PTPN5 P54829 1/20 0.55
▸ LMNA P02545 2/20 0.55
▸ GAA P10253 2/20 0.55
▸ DUSP3 P51452 1/20 0.53
▸ KMT2A Q03164 3/20 0.51
▸ TRPV1 Q8NER1 3/20 0.51
▸ ALOX12 P18054 1/20 0.50
▸ HSD17B10 Q99714 2/20 0.49
▸ USP2 O75604 1/20 0.49
▸ POLB P06746 1/20 0.49
▸ MEN1 O00255 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ CYP1A2 P05177 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14073911 0.93 MAPT (0.56) MAPTALDH1A1PTPN5LMNAGAA
SCHEMBL14073383 0.87 KMT2A (0.56) ALDH1A1PTPN5LMNAGAAKMT2A
SCHEMBL14073539 0.80 KMT2A (0.53) MAPTALDH1A1LMNAKMT2ATRPV1
SCHEMBL14073095 0.76 MAPT (0.60) MAPTALDH1A1LMNAKMT2ATRPV1
SCHEMBL14073667 0.75 KDM4E (0.60) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL14073519 0.74 KMT2A (0.55) MAPTALDH1A1LMNAKMT2ATRPV1
SCHEMBL4576855 0.73 ALDH1A1 (0.62) MAPTALDH1A1LMNAGAAKMT2A
SCHEMBL27652513 0.73 MAPT (0.62) MAPTALDH1A1LMNAKMT2ATRPV1
SCHEMBL14073548 0.73 KMT2A (0.60) MAPTALDH1A1KMT2ATRPV1POLB
SCHEMBL14073761 0.72 MAPT (0.53) MAPTALDH1A1LMNAKMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety ALANTOS PHARMACEUTICALS HOLDING, INC. 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221093-A1 Metalloprotease inhibitors containing a heterocyclic moiety MMP12, MMP13, MMP25 MAPT 3986/4885ALDH1A1 714/4885PTPN5 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback